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Aims: To identify the incidence of allergic conjunctivitis in patients with allergic rhinitis.
Methods: One hundred and eighty seven consecutive patients with allergic rhinitis (AR) were directly questioned if
they have allergic conjunctivitis (AC) and this was clarified using standard screening questions relating to red, itchy
and watery eyes recorded through a total ocular symptom score (TOSS). Patients were also asked about further
symptoms that may be attributable to AC: eyelid dermatitis, frequent blinking; eye sensitivity and frontal headache
from squinting or. blinking. All patients were given a drop of olopatadine hydrochloride 0.1% in each eye to help
identify “silent” disease. 20 healthy non-atopic controls were also treated with olopatadine drops and questioned
on ocular symptoms.
Results: Fifty five percent of patients with AR were identified as having AC by direct questioning and the use of
the TOSS questionaire. A further 41% were identifiable by asking additional questions and performing therapeutic
challenge with olopadatine.
Conclusions: AC is a frequent comorbid condition occurring in 95% of our patients with AR. Only 55% of patients
were able to identify that they had AC based on standard screening questions. Additional specific questioning and
a therapeutic challenge in suspected patients can help identify patients who may benefit from treatment of AC.Background
Allergic conjunctivitis (AC) commonly manifests as itchy,
watering or red eyes, which comprise the symptoms of the
total ocular symptom scores (TOSS) [1-3].
The incidence of AC in developed countries is 20% [4-6]
with a high co-morbidity of allergic rhinitis (AR) [5,6].
Recognition of AC is unreported even in patients with
recognised AR [6,7]. Under-recognition of AR is common,
with the proportion of undiagnosed AR patients ranging
from 25–60% [8].
Clinically, it is apparent that AC patients have heigh-
tened sensitivity, tending to blink and squint more, con-
tributing to frontal tension headaches. Rubbing of eyelids
can contribute to dermatitis, with patients focusing more
on the dermatitis than conjunctival symptoms.
Olopatadine hydrochloride 0.1% was selected for its
efficacy in AC, providing negligible side effect profile
and rapid onset of action, evident from five minutes post
administration [9-12].* Correspondence: daniel.c.r.williams@gmail.com
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Identify the incidence of AC in patients with AR.Methods
One hundred and eighty seven consecutive patients –
paediatrics and adults, during pollen season, with Allergist
diagnosed AR attending an outpatient clinic in Southport,
on the Gold Coast, were directly questioned if they have
AC, clarified by using standard screening questions of red,
itchy and watery eyes and quantified by TOSS. Patients
were asked about indirect symptoms that may be attribut-
able to AC: eyelid dermatitis, frequent blinking, eye sensi-
tivity and frontal headache. Patients were given a drop of
Olopatadine in each eye to help identify “silent” disease.
Patients were prospectively diagnosed with allergic rhin-
itis based on clinical history, examination and concurrent
skin prick testing by an allergy specialist. Patients were
instructed not to take antihistamines for at least 48 hours
prior to assessment.
Twenty controls without a clinical history of AR or AC
were also treated with olopatadine drops to determine ifl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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hydrochloride.
We did not note history of lasik surgery or pterygia in
any of our patients, nor were any of our participants wea-
ring contacts at the time of olopatadine administration.
Ethics approval was obtained from Griffith University
Human Research Ethics Committee.
This trial was registered with Australia New Zealand
Clinical Trials Registry (ANZCTR).
Data was analyzed using Microsoft Excel data-base
software (Microsoft Corp., Redlands, CA) using a paired
t-test for pre and post TOSS with Olopatadine challenge.
A Pearson correlation coefficient was used to compare
relationship between TOSS positivity and presence of
additional symptoms and the presence of symptoms and
response to a therapeutic challenge with olopatadine
Results
Fifty three percent of patients identified themselves as
having AC on direct questioning and enquiring about
specific TOSS symptoms. Additional possible symptoms
attributable to AC were squint 51%, blinking 52%, frontal
headache 60% and eyelid dermatitis 45%.
Olopatadine reduced TOSS scores within 5 minutes of
treatment (1.34 +/− 1.66 vs 0.486 +/− 0.83. p < 0.01). 146
(78.1%) subjects noted improvement verses 41 (21.9%)
noting no change in ocular symptoms. Based on a nega-
tive history of AC and baseline TOSS of 0, therapeutic
challenge of Olopatadine identified 77 (41.2%) silent
sufferers of AC.
No effect on TOSS was observed in control patients
treated with olopatadine.
One hundred and sixty six (88.8%) AC subjects were
identified through TOSS symptoms. Plausible indirect
AC symptoms detected 158 (84.5%) subjects. However,
combining standard TOSS and additional questions
detected 177 (94.7%) AC subjects. Presence of add-
itional ocular symptoms correlated both with TOSS
responses and beneficial effect of a therapeutic chal-
lenge with Olopatadine (r = 0.60 , P < 0.05).
Discussion
AC was identified in 53.5% of patients with AR using
direct questioning in relation to history of AC. This is
comparable with other studies [6,7,13-18]. Specific ques-
tioning regarding indirect symptoms increased the inci-
dence of AC in patients with AR to 94.7%. Olopatadine
therapeutic challenge was performed in 20 healthy, non-
atopic controls to ensure there was no non-specific
lubricating effect of the eye drop.
As this was a therapeutic challenge, a lubricant could
have improved symptoms and it would most likely help
patients with allergic conjunctivitis. There was no im-
provement in controls that were given this lubricanteffect and hence TOSS improvement can be attributed
to olopatadine, not to non-specific lubricating effect.
The co-existence of AC is well recognised in patients
with AR [6,7,13-18] although co-reporting frequency
may be as low as 40%. Under-recognition of allergic con-
junctivitis may be due to patients and physicians paying
more attention to allergic comorbidities such as AR or
rhinitis or the under-appreciation of the variability of
eye symptoms in patients with AC [6,19-21].
Our study confirms patients have an under-appreciation
of symptoms, even when prompted with specific ques-
tions, and the value of a therapeutic challenge. Our data
suggests approximately 40% of AR patients felt their
symptoms represented as normal. This is significant
because the presence and lack of treatment of AC contri-
butes negatively to their quality of life [22].
Limitations of this study include; it was an open clinical
audit and direct survey questions were used. Questions of
children were occasionally influenced by their parent’s
answers or prompting. Headache is a symptom associated
with AR [3] and may not localise towards ocular symp-
toms. However we did find an association with a history
of headache and response to a therapeutic challenge.
Conclusion
In conclusion, the standard AC screening questions iden-
tified just over half of the patients with AC. As suggested
by others, the absence of a history does not negate the
value of examining the conjunctiva. Additionally we sug-
gest that symptoms of blinking, squinting, eyelid der-
matitis and frontal headache and use of olopatadine
hydrochloride eye drops can help identify patients with
“silent” symptoms.
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